Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-Reference-Cited by-同舟云学术

Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients

Published:2024-07-29 Issue:9 Volume:79 Page:2400-2402
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Barone Federico¹²,Giacomelli Andrea¹²^ORCID,Casalini Giacomo²,Corbellino Mario²,Lai Alessia¹^ORCID,Gori Andrea¹³⁴,Antinori Spinello¹²^ORCID

Affiliation:

1. Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano , Milan , Italy

2. III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan , Italy

3. II Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan , Italy

4. Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano , Milan , Italy

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jac/article-pdf/79/9/2400/58998638/dkae234.pdf

Reference10 articles.

1. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients;Wu;J Antimicrob Chemother,2024

2. Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: a prospective cohort study;Calderón-Parra;Int J Antimicrob Agents,2024

3. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies;Bruel;Nat Med,2022

4. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages;Touret;iScience,2023

5. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies;Planas;Nat Commun,2023